00:00It's Benzinga, bringing Wall Street to Main Street.
00:02India's Sun Pharmaceutical Industries agreed to acquire U.S. drugmaker Organon in an $11.75 billion deal
00:10to expand beyond lower-margin generic drugs, according to the Wall Street Journal.
00:16Sun will pay $14 per share in cash, the two companies said in a joint statement late Sunday.
00:21The acquisition will position Sun as a top three player in global women's health products.
00:27Organon sells contraceptives, including Nexplanon and the fertility drug Follestim,
00:32and reported $6.2 billion in 2025 revenue.
00:37Sun has historically focused on generic drugs but has expanded its branded prescription portfolio
00:42in dermatology, ophthalmology, and skin cancer, which now makes up about 20% of sales.
00:48Organon shares have fallen more than 60% since 2022 due to stagnant sales.
00:52Organon shares rose 17.2% to $13.20 Monday.
00:58The deal is expected to close in early 2027, pending approvals,
01:02and will be funded with cash and bank financing.
01:04For all things money, visit Benzinga.com.
Comments